Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Milena Nicoloso"'
Autor:
Michele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, Lucia Bortot, Davide Lombardi, Milena Nicoloso, Simona Scalone, Giorgio Giorda, Gustavo Baldassarre, Roberto Sorio, Fabio Puglisi
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 11, p 3805 (2020)
Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with plati
Externí odkaz:
https://doaj.org/article/5b7a589c3ab34c899b1a7d4bcf07c465
Autor:
Colin Dinney, Menashe Bar-Eli, David McConkey, Arlene Siefker-Radtke, Hua Wang, George Calin, Ameeta Arora, Milena Nicoloso, Wei Qi, Woonyoung Choi, Meng Zhong, Liana Adam
Purpose: The epithelial-to-mesenchymal transition (EMT) is a cell development-regulated process in which noncoding RNAs act as crucial modulators. Recent studies have implied that EMT may contribute to resistance to epidermal growth factor receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3d8c9e63d5544adae6b58e2b7d997a
https://doi.org/10.1158/1078-0432.c.6517474
https://doi.org/10.1158/1078-0432.c.6517474
Autor:
Colin Dinney, Menashe Bar-Eli, David McConkey, Arlene Siefker-Radtke, Hua Wang, George Calin, Ameeta Arora, Milena Nicoloso, Wei Qi, Woonyoung Choi, Meng Zhong, Liana Adam
Conflict of Interest Form 1 from miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42c55b3ae9e331773dec9c92877b6585
https://doi.org/10.1158/1078-0432.22440103
https://doi.org/10.1158/1078-0432.22440103
Autor:
Priyabrata Mukherjee, George A. Calin, Simona Rossi, Angelica Cortez, Enfeng Wang, Rochelle Arvizo, Milena Nicoloso, Resham Bhattacharya
Oncogenic activation of Bmi-1 is found in a wide variety of epithelial malignancies including ovarian cancer, yet a specific mechanism for overexpression of Bmi-1 has not been determined. Thus, realizing the immense pathologic significance of Bmi-1 i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e577e8b9d5da64aca4555002e00e511
https://doi.org/10.1158/0008-5472.c.6499994.v1
https://doi.org/10.1158/0008-5472.c.6499994.v1
Autor:
Priyabrata Mukherjee, George A. Calin, Simona Rossi, Angelica Cortez, Enfeng Wang, Rochelle Arvizo, Milena Nicoloso, Resham Bhattacharya
Supplementary Figure 1B from MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::139c5f436e5945f91b4dd13935779ad2
https://doi.org/10.1158/0008-5472.22381829.v1
https://doi.org/10.1158/0008-5472.22381829.v1
Autor:
Priyabrata Mukherjee, George A. Calin, Simona Rossi, Angelica Cortez, Enfeng Wang, Rochelle Arvizo, Milena Nicoloso, Resham Bhattacharya
Supplementary Figure 2A from MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a267a0582bd9e651d54cd8eba531005d
https://doi.org/10.1158/0008-5472.22381826.v1
https://doi.org/10.1158/0008-5472.22381826.v1
Autor:
Tania Pivetta, Brenno Pastò, Martina Urbani, Elisabetta Benozzi, Nicola De Pascalis, Tiziana Perin, Mario Mileto, Bruno Pasquotti, Erica Piccoli, Lorenzo Vinante, Chiara Bampo, Silvia Bolzonello, Mattia Garutti, Milena Nicoloso, Serena Corsetti, Simona Scalone, Lucia da Ros, Paola di Nardo, Camilla Lisanti, Simon Spazzapan, Barbara Belletti, Michele Bartoletti, Lorenzo Gerratana, Samuele Massarut, Fabio Puglisi
Publikováno v:
Cancer Research. 83:P4-02
Background: Over the last years, the management of patients with node positive early breast cancer has gone through important innovations. On the medical side, new targeted therapies such as olaparib and abemaciclib have been introduced, with promisi
Autor:
Michele Bartoletti, Marcella Montico, Roberta Mazzeo, Marco De Scordilli, Lucia Musacchio, Emilio Lucia, Giorgio Giorda, Samuele Massarut, Martina Urbani, Gianmaria Miolo, Alessandra Viel, Mattia Garutti, Lucia Da Ros, Simona Scalone, Milena Nicoloso, Serena Corsetti, Roberto Sorio, Domenica Lorusso, Sandro Pignata, Fabio Puglisi
Publikováno v:
Journal of Clinical Oncology. 40:5566-5566
5566 Background: As the prognosis of BRCA-related advanced ovarian cancer (AOC) continues to improve thanks to the introduction of targeted therapies like poly ADP-ribose polymerase inhibitors (PARPi) and bevacizumab, the occurrence of second primary